Tamoxifen gynecological side effects

المؤلفون

  • Ghufran .J. E.Alsereah Basra Medical College

DOI:

https://doi.org/10.28922/qmj.2015.11.20.213-218

الملخص

Prospective comparative study done in basrah maternity and child hospital over a period of two years from 2002- 2004 , on breast cancer patients treated with tamoxifen which is estrogen receptors modulators with paradoxical effects ( agonist on some tissue and antagonist on others. This study aimed To compare side effect of tamoxifen on both studied groups Premenopausal and postmenopausal.
This study included96 Symptomatic pre and postmenopausal breast cancer treated patients with tamoxifen assassed by history and then examination was performed
Then endometrium assessed by transabdominal ultrasound to check thickness then almost all patients subjected to endometrial biopsy under general anesthesia, about 45.8% of patients between 50-60 years of age 41.6% of patients had advanced stages of cancer , vaginal bleeding which is the most common symptom symptoms presented in 68.7% ,while 22.8% , 8.28% had vaginal discharge and pain respectively.
ultrasound findings showed 22.9% endometrial thickness less than 6mm , 41.6% endometrial thickness 1 cm and more ,10.3% showed polyps and fibroid . no statistical difference between pre and postmenopausal inUSS findings with p value = 7.81, x2= 13.7, df=3
21.2% showed atrophic endometrium, 16.9% showed endometrial hyperplasia , bulk 44.6% showed non secretory ( proliferative) , with no cases of endometrial carcinoma . No, statistical difference between pre and postmenopausal findingsP value = 9.49 , x2 8.652 , df= 4 .In conclusion the main sharing symptoms in both groups was vaginal bleeding, USS had a poor predictive value in detecting changes in both studied group
Our study did not confirm risk of endometrial carcinoma , with no statistical difference in risk of hyperplasia between pre and postmenopausal studied groups.

التنزيلات

منشور

2017-07-23

إصدار

القسم

Articles